Intradermal Delivery of Vaccines: Potential Benefits and Current challenges/Injection Intradermique De Vaccines: Les Defies Potentials et Les Defies actuels/Administracion De Vacunas Por Via Intradermica: Posibles Beneficios Y Retos Actuales

By Hickling, J. K.; Jones, K. R. et al. | Bulletin of the World Health Organization, March 2011 | Go to article overview
Save to active project

Intradermal Delivery of Vaccines: Potential Benefits and Current challenges/Injection Intradermique De Vaccines: Les Defies Potentials et Les Defies actuels/Administracion De Vacunas Por Via Intradermica: Posibles Beneficios Y Retos Actuales


Hickling, J. K., Jones, K. R., Friede, M., Zehrung, D., Chen, D., Kristensen, D., Bulletin of the World Health Organization


Introduction

Most vaccines are delivered by the intramuscular or subcutaneous routes using a needle and syringe; the intradermal route is only widely used for the administration of Bacille Calmette-Guerin and rabies vaccines. However there is renewed interest in intradermal vaccine delivery, driven by the fact that the dermis and epidermis of human skin are rich in antigen-presenting cells, suggesting that delivery of vaccines to these layers, rather than to muscle or subcutaneous tissue, should be more efficient and induce protective immune responses with smaller amounts of vaccine antigen.

Clinicaltrials investigating intradermal delivery and its potential for dose-sparing have been conducted with several different vaccines, with variable results. These have been reviewed in a recent report from the Program for Appropriate Technology in Health (PATH) and the World Health Organization (WHO). (2) For some vaccines, there has been a clear demonstration of dose-sparing by intradermal delivery; however, there ate several gaps in knowledge as well as developmental and operational challenges to overcome if the benefits of using intradermal delivery are to be fully realized.

Potential benefits

Dose-sparing arising from intradermal delivery of vaccines could be beneficial to immunization programmes, particularly in resource-poor settings, by potentially reducing the per-injection cost (including transport and storage) of vaccines because more doses might be obtained from the existing vaccine presentation.

Dose-sparing might also "stretch" the availability of vaccines in cases where supply is limited by manufacturing capacity. This is probably most relevant for pandemic influenza vaccines where global production capacity limits access to a vaccine at the start of a pandemic. (3) In 2009, H1N1 vaccine was not available in most low-income countries until 8 months after WHO's declaration of the influenza pandemic. (4)

Other vaccines with potential supply constraints include yellow fever and inactivated poliovirus vaccines. (5,6) The level of demand for inactivated poliovirus vaccine in the period following eradication of wild-type polioviruses and the end of the use of oral poliovirus vaccines is uncertain, but modelling suggests that there could be a "demand spike" and supply shortage of. inactivated poliovirus vaccine during this period. (6)

New delivery devices

New devices for easier, more reliable intradermal delivery as alternatives to the currently used Mantoux technique ate being developed. (2,7) Some of the devices such as disposable-syringe jet injectors ate needle-free and could therefore reduce of eliminate needlestick injuries and the costs associated with their treatment, estimated at USS 535 million per year worldwide. (8) Other intradermal delivery devices such as microneedle patches are likely to occupy less volume than vials of prefilled syringes, thereby reducing demands on cold-chain capacity.

Current clinical research

The recent PATH and WHO report reviewed more than 90 clinical trials of intradermal delivery with vaccines against 11 diseases. (2) For some vaccines, notably influenza and rabies vaccines, intradermal delivery of reduced doses resulted in equivalent immune responses to the standard dose delivered by the standard route. Data from trials with hepatitis B vaccine were more variable, but also regarded as encouraging. (9) Promising data demonstrating dose-sparing have also been obtained with other vaccines including inactivated poliovirus, yellow fever and hepatitis A vaccines. (2)

Results from clinicaltrials publishcd since the completion of the report provide further evidence for dose-sparing using the intradermal route. One study compared equivalent doses of modified vaccinia Ankara delivered by subcutaneous, intramuscular and intradermal routes; equivalent immune responses and protection against vaccinia-virus challenge were induced with intradermal doses ten-fold lower than those delivered by intramuscular or subcutaneous injection.

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
Loading One moment ...
Project items
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited article

Intradermal Delivery of Vaccines: Potential Benefits and Current challenges/Injection Intradermique De Vaccines: Les Defies Potentials et Les Defies actuels/Administracion De Vacunas Por Via Intradermica: Posibles Beneficios Y Retos Actuales
Settings

Settings

Typeface
Text size Smaller Larger
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

While we understand printed pages are helpful to our users, this limitation is necessary to help protect our publishers' copyrighted material and prevent its unlawful distribution. We are sorry for any inconvenience.
Full screen

matching results for page

Cited passage

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

Cited passage

Welcome to the new Questia Reader

The Questia Reader has been updated to provide you with an even better online reading experience.  It is now 100% Responsive, which means you can read our books and articles on any sized device you wish.  All of your favorite tools like notes, highlights, and citations are still here, but the way you select text has been updated to be easier to use, especially on touchscreen devices.  Here's how:

1. Click or tap the first word you want to select.
2. Click or tap the last word you want to select.

OK, got it!

Thanks for trying Questia!

Please continue trying out our research tools, but please note, full functionality is available only to our active members.

Your work will be lost once you leave this Web page.

For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

Already a member? Log in now.

Are you sure you want to delete this highlight?